newsfilter
← Latest News
ACCESS Newswire·

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor typesCD3 bispecific